Term ends no later than Jun 17, 2030 · Medium confidence
20-year base term ends Jun 17, 2030
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Isis Pharmaceuticals, Inc.
Filed Feb 9, 2015 as application 14/617,388 · Granted Aug 1, 2017
Base term, 20 years from filing
Today
2010
2030
Clock starts
Jun 17, 2010
Jun 17, 2010
Ends no later than
Jun 17, 2030
Jun 17, 2030
Granted
Aug 1, 2017
Aug 1, 2017
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
10
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 17, 2010, when application PCT/US2010/039077, the earliest non-provisional in its chain, was filed (this one was filed Feb 9, 2015) | Jun 17, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Jun 17, 2030 | Medium confidence |
This family
| Application PCT/US2010/039077 | PCT application no patent term | no patent term |
| US 8,980,853 | In force Nov 2030 | Nov 2030 |
| US 9,717,750 | this patent no later than Jun 2030 | no later than Jun 2030 |
| Application 15/630,445 | Abandoned not computed | not computed |
| Application 15/892,560 | Abandoned not computed | not computed |
| Application 16/708,739 | Abandoned not computed | not computed |
| Application 17/479,081 | Abandoned not computed | not computed |
| Application 17/751,816 | Abandoned not computed | not computed |
8 of 10 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 24, 2016 Reel 37915, frame 53 | Isis Pharmaceuticals, Inc. | Ionis Pharmaceuticals, Inc. | Change of Name |
| Oct 18, 2016 Reel 40415, frame 271 | Ionis Pharmaceuticals, Inc. | Biogen Ma Inc. | Assignment of Assignor's Interest |
| Oct 24, 2016 Reel 40104, frame 860 | Krainer, Adrian R.; Hua, Yimin | Cold Spring Harbor Laboratory | Assignment of Assignor's Interest |
| Feb 14, 2017 Reel 41253, frame 268 | Passini, Marco A.; Shihabuddin, Lamya; Cheng, Seng H.; Klinger, Katherine W. | Genzyme Corporation | Assignment of Assignor's Interest |
| Feb 14, 2017 Reel 41253, frame 307 | Bennett, C. Frank; Hung, Gene; Rigo, Frank | Isis Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Feb 14, 2017 Reel 41253, frame 329 | Genzyme Corporation | Isis Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jun 2030
Term ends no later than Jun 17, 2030. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Jun 17, 2030. We will not guess the cap.
Citations
26
later US patents cite this one
That is top 25% of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.